Aurobindo to acquire dermatology and oral solids businesses from Sandoz Inc., USA

Aurobindo Pharma announced that wholly owned subsidiary, Aurobindo Pharma USA Inc., USA, has entered into an agreement to acquire certain assets from Sandoz Inc., USA ("Sandoz"), a Novartis Division, comprising a market leading dermatology business and a portfolio of oral solid products along with commercial and manufacturing infrastructure in the US. The acquisition will be on debt free and cash free basis.

Aurobindo and Sandoz will enter into a transitional services agreement to support the ongoing growth plans of the businesses being acquired by Aurobindo. The transaction will be an all cash transaction which Aurobindo will finance through a fully committed debt facility.

 

This US acquisition is in line with Aurobindo's strategy to strengthen and grow its global business and to expand and enhance its product portfolio offerings in key therapeutic areas.

The transaction is expected to close in the course of 2019 following the completion of customary closing conditions, including FTC clearance.

This is a carved out business of Sandoz in US and the product portfolio consists of Dermatology, CNS, Alimentary Tract/Metabolic, Women's Health, Anti-infectives, Systemic Hormones and others along with three manufacturing facilities situated in Hicksville and Melville in New York and Wilson in North Carolina.

Powered by Capital Market - Live News